SCHEMBL4300735

SCHEMBL4300735

CCOCc1nc2cnc(C)c(C)c2n1NC1CCOCC1

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
PDE1B Q01064 12/20 0.34
PDE1C Q14123 10/20 0.34
PDE4D Q08499 2/20 0.33
BRD4 O60885 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
PDE1A P54750 7/20 0.33
PDE5A O76074 1/20 0.33
MAPK1 P28482 1/20 0.32
TYK2 P29597 1/20 0.32
JAK3 P52333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14466078 0.85
SCHEMBL4305064 0.82 P2RY12 (0.32) TLR7MAPK1
SCHEMBL4760996 0.82 TLR7 (0.45) JAK2JAK1PDE1BPDE1CPDE4D
SCHEMBL13663019 0.81 PDE1B (0.42) PDE1BPDE1CTLR7PDE1A
SCHEMBL4302583 0.79 TLR7 (0.33) PDE4DTLR7PDE5A
SCHEMBL4302882 0.79 TLR7 (0.43) TLR7PDE5A
SCHEMBL12702247 0.72 CNR2 (0.33) BRD4TLR7
SCHEMBL4754407 0.72 TLR7 (0.38) JAK2JAK1TLR7PDE5AMAPK1
SCHEMBL13663020 0.71 TLR7 (0.51) PDE1BPDE1CTLR7PDE1A
SCHEMBL13663014 0.68 TLR7 (0.37) TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. 2009-10-29 US disclosed
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. 2009-10-29 US disclosed
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. 2009-10-29 US disclosed
EP-1968587-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS Coley Pharmaceutical, Inc. (US) 2008-09-17 EP disclosed
WO-2007075468-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-07-05 WO disclosed
WO-2007075468-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS IL2, IL4I1, IFNG JAK2 65/4885JAK1 53/4885PDE1B 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.